| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 506.9 | 466.2 | 471.8 |
| Other income | 2.0 | 2.2 | 0.8 |
| Total income | 522.1 | 469.7 | 485.4 |
| Profit before exceptional items & tax | -12.9 | -19.6 | -13.0 |
| Exceptional items | 37.1 | 97.3 | -0.5 |
| Profit before tax | 24.2 | 77.7 | -13.5 |
| Net profit | 19.5 | 65.4 | -9.2 |
| Operating margin | 4.6% | 16.5% | -2.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -70.20% |
|---|---|
| Revenue, year on year | +7.40% |
| Operating profit, year on year | -8.00% |
| Operating profit, quarter on quarter | +31.70% |
NSE results filing, NSE: INDOCO. Figures extracted from the filing.
Indoco Remedies Ltd: key numbers
- Share price
- ₹213.75
- Market cap
- ₹1,973 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 61.8×Sector 46.1×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Employee Stock Options
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Other Announcement
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies Board Meeting Date
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
- Value
- ₹0.01 Cr